AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10626189 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural beta-IFN (6 MU/tiw for 6 months followed by 3 MU/tiw for 6 months)
Number of subjects: 61
Study 10626189 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 61
Study 8955543 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary restraint in 16-year-old girls under high anxiety conditions
Number of subjects: 0
Study 8955543 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary restraint in both age groups for forbidden foods
Number of subjects: 0
Study 8955543 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary restraint in 16-year-old girls
Number of subjects: 0
Study 8955543 — intervention group
Group type: COMPARATOR
Intervention: Permitted food consumption
Number of subjects: 0
Study 2011422 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 536
Study 2011422 — intervention group
Group type: COMPARATOR
Intervention: Myringotomy alone
Number of subjects: 536
Study 2011422 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin alone
Number of subjects: 536
Study 2011422 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin with myringotomy
Number of subjects: 536
Study 7048248 — intervention group
Group type: EXPERIMENTAL
Intervention: Isaxonine
Number of subjects: 0
Study 7048248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30918967 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG) 50 mg twice daily during and 2 weeks after tuberculosis therapy, then 50 mg once daily for 52 weeks
Number of subjects: 113
Study 30918967 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (EFV) 600 mg daily with 2 nucleoside reverse transcriptase inhibitors for 52 weeks
Number of subjects: 113
Study 30573417 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved infant and young child feeding (IYCF)
Number of subjects: 668
Study 30573417 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (non-IYCF)
Number of subjects: 668
Study 30573417 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved water, sanitation, and hygiene (WASH)
Number of subjects: 668
Study 30573417 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (non-WASH)
Number of subjects: 668
Study 29066437 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 4000 IU (100 μg) daily
Number of subjects: 305
Study 29066437 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 2000 IU (50 μg) daily
Number of subjects: 305
Study 29066437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study 29066437 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic measures
Number of subjects: 305
Study 29066437 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma N-terminal prohormone of brain natriuretic peptide
Number of subjects: 305
Study 26087472 — intervention group
Group type: EXPERIMENTAL
Intervention: SPARC (Sheffield Profile for Assessment and Referral for Care) at baseline, n = 87
Number of subjects: 182
Study 26087472 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control (no SPARC at baseline), n = 95
Number of subjects: 182
Study 26087472 — intervention group
Group type: EXPERIMENTAL
Intervention: SPARC and Waiting-list control
Number of subjects: 182
Study 24740208 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy fat intake (measured by biomarkers trans‐16:1n‐7, 15:0, and 17:0)
Number of subjects: 32
Study 24740208 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy fat intake (specifically phospholipid trans‐16:1n‐7)
Number of subjects: 32
Study 24740208 — intervention group
Group type: COMPARATOR
Intervention: Control group (BMI- and age-matched)
Number of subjects: 32
Study 22855557 — intervention group
Group type: EXPERIMENTAL
Intervention: Off β-blockers (Off-BB)
Number of subjects: 19
Study 22855557 — intervention group
Group type: COMPARATOR
Intervention: On β-blockers (On-BB)
Number of subjects: 19
Study 22855557 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-BB
Number of subjects: 19
Study 22855557 — intervention group
Group type: COMPARATOR
Intervention: On-BB
Number of subjects: 19
Study 19395688 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release bupropion
Number of subjects: 85
Study 19395688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 17393618 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 0
Study 17393618 — intervention group
Group type: COMPARATOR
Intervention: Control group (no leukogenic drugs)
Number of subjects: 0
Study 15733486 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment with indocyanine green solution (1 mg/ml) injected submucosally and diode laser (power 10 watts) applied to the surface from the esophagogastric junction to 5 cm above it.
Number of subjects: 42
Study 15733486 — intervention group
Group type: COMPARATOR
Intervention: Control group without any treatments.
Number of subjects: 42
Study 11555762 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide aqueous nasal spray (n = 9)
Number of subjects: 20
Study 11555762 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 20
Study 9683388 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine devices (IUD)
Number of subjects: 6648
Study 9683388 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 6648
Study 9683388 — intervention group
Group type: COMPARATOR
Intervention: Menstruating women (general population)
Number of subjects: 6648
Study 9683388 — intervention group
Group type: COMPARATOR
Intervention: Post-menopausal women
Number of subjects: 6648
Study 9683388 — intervention group
Group type: COMPARATOR
Intervention: Dietary iron intake
Number of subjects: 6648
Study 9683388 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 6648
Study 8152576 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 90
Study 8152576 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 90
Study 8152576 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 90
Study 3244540 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymomodulin
Number of subjects: 40
Study 3244540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29473481 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal sensorimotor exercise training
Number of subjects: 52
Study 29473481 — intervention group
Group type: COMPARATOR
Intervention: Functional exercise training (control group)
Number of subjects: 52
Study 28330497 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-IgE treatment (omalizumab) for 6 months
Number of subjects: 62
Study 28330497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 26435229 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy administered to 25 patients
Number of subjects: 53
Study 26435229 — intervention group
Group type: COMPARATOR
Intervention: No physical therapy administered to 28 patients
Number of subjects: 53
Study 24331343 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of general and epidural anesthesia
Number of subjects: 60
Study 24331343 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 60
Study 21149672 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG+CSA
Number of subjects: 88
Study 21149672 — intervention group
Group type: COMPARATOR
Intervention: BSC
Number of subjects: 88
Study 18364043 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) treatment by mothers of febrile children, supported by local women group leaders; CQ was regularly supplied through a revolving fund from local health centres.
Number of subjects: 1076
Study 18364043 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 1076
Study 17074200 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation
Number of subjects: 20
Study 17074200 — intervention group
Group type: COMPARATOR
Intervention: Control group (no RF ablation)
Number of subjects: 20
Study 12007953 — intervention group
Group type: EXPERIMENTAL
Intervention: EBRT (50.4 Gy/28 fractions) with concurrent continuous infusion of 5-FU (200 mg/m²/day)
Number of subjects: 31
Study 12007953 — intervention group
Group type: COMPARATOR
Intervention: No chemoradiation
Number of subjects: 31
Study 12007953 — intervention group
Group type: EXPERIMENTAL
Intervention: EBRT with concurrent continuous 5-FU infusion
Number of subjects: 31
Study 12007953 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 31
Study 10481772 — intervention group
Group type: EXPERIMENTAL
Intervention: Coumarin/Troxerutine (Venalot Depot)
Number of subjects: 48
Study 10481772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 8577007 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-supplemented diet
Number of subjects: 30
Study 8577007 — intervention group
Group type: COMPARATOR
Intervention: Isonitrogenous control diet
Number of subjects: 30
Study 8577007 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets (Glutamine-supplemented and Isonitrogenous control)
Number of subjects: 30
Study 1684678 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (KS) 40-80 mg daily
Number of subjects: 51
Study 1684678 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (KS) combined with triampur
Number of subjects: 51
Study 1684678 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (KS) combined with propranolol (PP)
Number of subjects: 51
Study 1684678 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (KS) combined with prazosin
Number of subjects: 51
Study 1684678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 1684678 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenergic blocker propranolol (PP)
Number of subjects: 51
Study 1684678 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic triampur
Number of subjects: 51
Study 1684678 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha 1-adrenergic blocker prazosin
Number of subjects: 51
Study 6122752 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined beta‐blocker‐chlorthalidone treatment
Number of subjects: 20
Study 6122752 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of a beta‐blocker
Number of subjects: 20
Study 6122752 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone monotherapy
Number of subjects: 20
Study 28699032 — intervention group
Group type: EXPERIMENTAL
Intervention: ME-CyA + prednisolone (PSL)
Number of subjects: 21
Study 28699032 — intervention group
Group type: COMPARATOR
Intervention: prednisolone (PSL) alone
Number of subjects: 21
Study 27185680 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mask (OM) ventilation
Number of subjects: 0
Study 27185680 — intervention group
Group type: COMPARATOR
Intervention: Face mask (FM) ventilation
Number of subjects: 0
Study 25664626 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants in the NELSON lung cancer screening trial
Number of subjects: 15822
Study 25664626 — intervention group
Group type: COMPARATOR
Intervention: Eligible nonresponders
Number of subjects: 15822
Study 23190762 — intervention group
Group type: EXPERIMENTAL
Intervention: Preinfarction angina
Number of subjects: 430
Study 23190762 — intervention group
Group type: COMPARATOR
Intervention: No preinfarction angina (Control)
Number of subjects: 430
Study 23190762 — intervention group
Group type: EXPERIMENTAL
Intervention: Preinfarction angina (anterior STEMI)
Number of subjects: 430
Study 23190762 — intervention group
Group type: COMPARATOR
Intervention: No preinfarction angina (anterior STEMI Control)
Number of subjects: 430
Study 23190762 — intervention group
Group type: EXPERIMENTAL
Intervention: Preinfarction angina (non-anterior STEMI)
Number of subjects: 430
Study 23190762 — intervention group
Group type: COMPARATOR
Intervention: No preinfarction angina (non-anterior STEMI Control)
Number of subjects: 430
Study 23190762 — intervention group
Group type: EXPERIMENTAL
Intervention: Preinfarction angina (female gender)
Number of subjects: 430
Study 23190762 — intervention group
Group type: COMPARATOR
Intervention: No preinfarction angina (female gender Control)
Number of subjects: 430
Study 23190762 — intervention group
Group type: EXPERIMENTAL
Intervention: Preinfarction angina (male gender)
Number of subjects: 430
Study 23190762 — intervention group
Group type: COMPARATOR
Intervention: No preinfarction angina (male gender Control)
Number of subjects: 430
Study 23190762 — intervention group
Group type: EXPERIMENTAL
Intervention: Preinfarction angina (ischemia time ≤ 4h)
Number of subjects: 430
Study 23190762 — intervention group
Group type: COMPARATOR
Intervention: No preinfarction angina (ischemia time ≤ 4h Control)
Number of subjects: 430
Study 23190762 — intervention group
Group type: EXPERIMENTAL
Intervention: Preinfarction angina (ischemia time > 4h)
Number of subjects: 430
Study 23190762 — intervention group
Group type: COMPARATOR
Intervention: No preinfarction angina (ischemia time > 4h Control)
Number of subjects: 430
Study 23190762 — intervention group
Group type: EXPERIMENTAL
Intervention: Preinfarction angina (after correction for baseline characteristics)
Number of subjects: 430
Study 21044933 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunonutrition feed supplemented with glutamine, arginine, omega-3 fatty acids, tributyrin, vitamin C, E, B-carotene, and micronutrients (zinc, selenium, chromium)
Number of subjects: 0
Study 21044933 — intervention group
Group type: COMPARATOR
Intervention: Control feed (isonitrogenous, isocaloric)
Number of subjects: 0
Study 21044933 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunonutrition feed
Number of subjects: 0
Study 21044933 — intervention group
Group type: COMPARATOR
Intervention: Control feed
Number of subjects: 0
Study 18656600 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoclip
Number of subjects: 699
Study 18656600 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 699
Study 16498702 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference Pricing (RP) for anti-hypertensive drugs
Number of subjects: 0
Study 16498702 — intervention group
Group type: COMPARATOR
Intervention: Public plan without RP
Number of subjects: 0
Study 12894958 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 2208
Study 11127163 — intervention group
Group type: EXPERIMENTAL
Intervention: Different surgical approaches for treating menorrhagia (not specified in detail)
Number of subjects: 1
Study 11127163 — intervention group
Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 1
Study 9374606 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterfactual thinking and hindsight bias
Number of subjects: 0
Study 9374606 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 8507812 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0
Study 8507812 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0
Study 3830040 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide diet
Number of subjects: 9
Study 3830040 — intervention group
Group type: COMPARATOR
Intervention: Normal low fat diet
Number of subjects: 9
Study 31218477 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3 (50,000 IU weekly for 12 weeks, followed by 2000 IU daily for 40 weeks)
Number of subjects: 93
Study 31218477 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose vitamin D3 (800 IU daily for 52 weeks)
Number of subjects: 93
Study 29339097 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax plus intravenous decitabine 20 mg/m2 (days 1-5 of each 28-day cycle)
Number of subjects: 57
Study 29339097 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax plus subcutaneous or intravenous azacitidine 75 mg/m2 (days 1-7 of each 28-day cycle)
Number of subjects: 57
Study 29339097 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax plus decitabine with posaconazole (CYP3A inhibitor)
Number of subjects: 57
Study 26705010 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal route
Number of subjects: 220
Study 26705010 — intervention group
Group type: COMPARATOR
Intervention: Oral route
Number of subjects: 220
Study 24824050 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced HIV pre‐ and post‐test counseling, legal support, and access to support groups at baseline, six and ten weeks postpartum
Number of subjects: 1480
Study 24824050 — intervention group
Group type: COMPARATOR
Intervention: Standard HIV testing and counseling (HTC) and two postpartum attention control sessions
Number of subjects: 1480
Study 22395837 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine 3 µ/kg/min
Number of subjects: 60
Study 22395837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 20856123 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine 25-50 mg/day
Number of subjects: 515
Study 20856123 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 20-40 mg/day
Number of subjects: 515
Study 18035433 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 0
Study 16028252 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic thrombolysis with recombinant tissue plasminogen activator (rtPA)
Number of subjects: 47
Study 16028252 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic thrombolysis with rtPA and GPIIb/IIIa receptor antagonist tirofiban
Number of subjects: 47
Study 16028252 — intervention group
Group type: COMPARATOR
Intervention: No thrombolysis (nontreated patients)
Number of subjects: 47
Study 12840617 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test (intermittent immersion of the hand into ice water)
Number of subjects: 76
Study 10794337 — intervention group
Group type: EXPERIMENTAL
Intervention: Predonated autologous whole blood
Number of subjects: 713
Study 10794337 — intervention group
Group type: EXPERIMENTAL
Intervention: Normovolemic hemodilution
Number of subjects: 713
Study 10794337 — intervention group
Group type: EXPERIMENTAL
Intervention: Red cell salvage
Number of subjects: 713
Study 10794337 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinfusion of shed mediastinal blood
Number of subjects: 713
Study 8851073 — intervention group
Group type: EXPERIMENTAL
Intervention: 27 degrees C
Number of subjects: 83
Study 8851073 — intervention group
Group type: COMPARATOR
Intervention: 21 degrees C
Number of subjects: 83
Study 1289514 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 240 mg SR
Number of subjects: 1464
Study 1289514 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone 25 mg
Number of subjects: 1464
Study 3890732 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose tetracycline (2 g)
Number of subjects: 62
Study 3890732 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-dose tetracycline (500 mg four times per day for 10 days)
Number of subjects: 62
Study 3890732 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose amoxicillin (3 g)
Number of subjects: 62
Study 31288480 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating while working on a computer
Number of subjects: 43
Study 31288480 — intervention group
Group type: COMPARATOR
Intervention: Eating quietly and at rest (control)
Number of subjects: 43
Study 30025397 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Formula (BSF) combined with enticavir (ETV) for 12 months
Number of subjects: 64
Study 30025397 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with enticavir (ETV) for 12 months
Number of subjects: 64
Study 27720506 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2mg oral clonidine one hour before the operation in addition to standard anesthesia procedure
Number of subjects: 52
Study 27720506 — intervention group
Group type: COMPARATOR
Intervention: Standard anesthesia procedure alone
Number of subjects: 52
Study 25082565 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential erlotinib 150 mg/d (day 2-16) + docetaxel (75 mg/m² day 1)
Number of subjects: 147
Study 25082565 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m² day 1) alone
Number of subjects: 147
Study 21176556 — intervention group
Group type: EXPERIMENTAL
Intervention: Levornidazole
Number of subjects: 143
Study 21176556 — intervention group
Group type: COMPARATOR
Intervention: Ornidazole
Number of subjects: 143
Study 15586364 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablative therapy (APC or PDT)
Number of subjects: 29
Study 15586364 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablative therapy (APC)
Number of subjects: 29
Study 12039395 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidarestat (SNK-860; 1 mg daily)
Number of subjects: 58
Study 12039395 — intervention group
Group type: COMPARATOR
Intervention: Epalrestat (150 mg daily)
Number of subjects: 58
Study 9577105 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully programmed edgewise appliance (FPA)
Number of subjects: 61
Study 9577105 — intervention group
Group type: COMPARATOR
Intervention: Partly programmed edgewise appliance (PPA)
Number of subjects: 61
Study 8120703 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial therapy
Number of subjects: 5400
Study 8120703 — intervention group
Group type: COMPARATOR
Intervention: Placebo or no drug
Number of subjects: 5400
Study 3164762 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual lorazepam (2 to 3 mg)
Number of subjects: 60
Study 3164762 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular diazepam (0.25 mg/kg)
Number of subjects: 60
Study 3164762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 11246935 — intervention group
Group type: EXPERIMENTAL
Intervention: Distant healing (anonymous, amulet, allowing for personal contact)
Number of subjects: 119
Study 11246935 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 119
Study 30291994 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective dose (Deff) with n = 0.5
Number of subjects: 203
Study 30291994 — intervention group
Group type: COMPARATOR
Intervention: Mean lung dose (MLD) with n = 1
Number of subjects: 203
Study 30291994 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking status
Number of subjects: 203
Study 29573665 — intervention group
Group type: EXPERIMENTAL
Intervention: dHR+ (ER+/PgR+)
Number of subjects: 571
Study 29573665 — intervention group
Group type: COMPARATOR
Intervention: sHR+ (ER+/PgR–)
Number of subjects: 571